Although this mutation has not proven any influence on chemotherapy or radiotherapy [158], the therapeutic activity of BRAF/MEK inhibitors has auspicious results [163], with near total GBM remission after 3 months of dabrafenib/trametinib treatment [163,164]. This evidence concerns the gene BRAF and glioblastoma.